Bromodomain and extra-terminal motif (BET) inhibition induces coordinated repression of the stem cell-related HOX signature in glioblastoma uncovering an epigenetic vulnerability
Abstract
Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epigenetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOXA genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate the deregulated epigenetic landscape and potential vulnerabilities in high-HOX GB.
Methods: GB-derived spheres (GS) were treated with the BETi (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression short-hairpin (sh)RNA for knockdown, ectopic HOXA10). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, Chromatin Immuno Precipitation sequencing (ChIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), promoter capture MicroC, and DNA methylation.
Results: BETi-mediated rapid, coordinated downregulation of the HOX-signature suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOXA genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression failed to reactivate the HOXA cluster or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high-HOX-GS revealed concerted activation of the HOXA region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC), and focal DNA hypomethylation. Architectural changes included altered CCCTC-binding factor (CTCF) interactions and increased promoter-anchored looping.
Conclusion: These results position the HOX-signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high-HOX GB.
Related
- Combined HDAC and ATM inhibition with radiation in preclinical glioblastoma models
- Pannexin 1 inhibition reduces tumorigenic properties of patient-derived glioblastoma cells through the HIPPO and Wnt signalling pathways
- Choline Kinase Alpha Inhibition is a Mutation Agnostic Therapeutic Vulnerability in Clonal Hematopoiesis
- Cell-state-dependent responses to PLK1 inhibition reveal a non-canonical microtubule-endolysosomal vulnerability in quiescent leukemia stem cells
- Coordinated inhibition of SOX9 and cell-cycle progression by microRNA-200 restricts sebaceous gland fate specification
BibTeX
@article{chiesi2026bromodomain,
title = {{Bromodomain and extra-terminal motif (BET) inhibition induces coordinated repression of the stem cell-related HOX signature in glioblastoma uncovering an epigenetic vulnerability}},
author = {Davide Chiesi and Pierre Bady and Mihalis V Xirouchakis and Carla Mendes Ferreira and Kedir S Mohammed and Monika E Hegi},
journal = {Neuro-Oncology Advances},
year = {2026},
month = oct,
doi = {10.1093/noajnl/vdag260},
url = {https://doi.org/10.1093/noajnl/vdag260},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Bromodomain and extra-terminal motif (BET) inhibition induces coordinated repression of the stem cell-related HOX signature in glioblastoma uncovering an epigenetic vulnerability
AU - Davide Chiesi
AU - Pierre Bady
AU - Mihalis V Xirouchakis
AU - Carla Mendes Ferreira
AU - Kedir S Mohammed
AU - Monika E Hegi
PY - 2026
DA - 2026/10/07
JO - Neuro-Oncology Advances
DO - 10.1093/noajnl/vdag260
UR - https://doi.org/10.1093/noajnl/vdag260
AB - Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epigenetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOXA genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate the deregulated epigenetic landscape and potential vulnerabilities in high-HOX GB. Methods: GB-derived spheres (GS) were treated with the BETi (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression short-hairpin (sh)RNA for knockdown, ectopic HOXA10). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, Chromatin Immuno Precipitation sequencing (ChIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), promoter capture MicroC, and DNA methylation. Results: BETi-mediated rapid, coordinated downregulation of the HOX-signature suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOXA genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression failed to reactivate the HOXA cluster or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high-HOX-GS revealed concerted activation of the HOXA region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC), and focal DNA hypomethylation. Architectural changes included altered CCCTC-binding factor (CTCF) interactions and increased promoter-anchored looping. Conclusion: These results position the HOX-signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high-HOX GB.
SN - 2632-2498
ER -